Sonoma Pharmaceuticals (SNOA) Cash & Equivalents (2010 - 2026)

Sonoma Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 55.36% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 55.36% decrease from a year earlier, with the FY2026 full-year figure at $2.4 million, down 55.36% from the prior year.
• Cash & Equivalents slipped to $2.4 million in Q1 2026 per SNOA's latest filing, from $2.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.4 million in Q1 2022 and bottomed at $2.1 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $3.4 million (2022), against an average of $3.7 million.
• Across the five-year window, Cash & Equivalents tumbled 69.12% in 2022 and jumped 117.62% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $2.6 million in 2022, then retreated by 8.66% to $2.4 million in 2023, then soared by 117.62% to $5.2 million in 2024, then tumbled by 51.09% to $2.6 million in 2025, then dropped by 6.33% to $2.4 million in 2026.
• Per Business Quant, the three latest SNOA Cash & Equivalents figures stand at $2.4 million (Q1 2026), $2.6 million (Q4 2025), and $3.0 million (Q3 2025).